scholarly journals Comparative Study of Compliance between Sofosbuvir and Interferon in the Management of Viral Hepatitis at Tertiary Care Hospital of Gambat, Sindh, Pakistan

Author(s):  
Sajid Ali ◽  
Zuheeb Ahmed ◽  
Marvi Metlo ◽  
Tahseen Ahmed ◽  
Shahzad Ali ◽  
...  

Introduction: Hepatitis can be defined as inflammation of the liver. Hepatitis may be acute or chronic. It is estimated that in 2017, approximately 15 million people suffered from Hepatitis in Pakistan suffering from hepatitis. 150–200 million people, or approximately ~3% of the world's population, are living with chronic Hepatitis C. Methodology: A descriptive cross-sectional study was conducted on 300 patients selected by purposive sampling who were reported with Hepatitis-C and co infection of Hepatitis-C + Hepatitis-B, at a tertiary care hospital Gambat. A series of questions were asked from reported patients regarding symptoms and compliance. Results: The results were analyzed by using SPSS-22. Among the 300 patients some were on sofosbuvir (n=150, 50%), which the others were on interferon (n=150, 50%). The findings showed that most of the patients on interferon were non-compliant (n=125,83.3%), and only (n=25, 16.7%) are compliant. Among non-compliant factors, fear from injection was reported in (n=42, 33.6), technique for injection (n=38, 30.4%), prolong duration of action (n=35, 28%), adverse drug reaction (n=26, 20.8%). Better compliance was observed with sofosbuvir (n=93, 62.8%) and non-compliant were (57, 38%). Conclusion: This study concluded that better compliance was achieved with sofosbuvir as compared to interferon, rate of ADR’S were also less with sofosbuvir.

2018 ◽  
Vol 8 (3) ◽  
pp. 170-173
Author(s):  
Zulfiqar Ali Shaikh ◽  
Javeria Shamim ◽  
Kelash Nankani

Background: Hepatitis C is among one of the major global health issues; which may cause chronic liver disease, end stage liver disease, and hepatocellular carcinoma; subsequently requiring liver transplant. For HCV, standard treatment is a combination therapy of ribavirin and interferon for six months. Ribavirin fostered hemolysis is a major treatment-associated adverse effect. Our study aimed to assess ribavirin induced anemia among Hepatitis C patients visiting Civil Hospital, Karachi. Methods: A hospital-based cross-sectional study which included 106 Hepatitis C patients, of 15-60 years' age, visiting CHK, a public sector tertiary care hospital, from October 2017 to January 2018 by using non-probability convenient sampling technique. Results: Total 106 patients participated, 53 (50.0%) were males and 53 (50.0%) were females. Mean (±SD) age was 37.05 (±10.793). Mean (±SD) duration of ribavirin use was 3.03 (±1.523) months. Around 16.0% had ribavirin dose reduction. All of them experienced weakness, fatigue and light-headedness, 59.4% developed microcytic hypochromic anemia, 23.6% had severe anemia. Mean (±SD) hemoglobin level before the onset of treatment was 12.78 (±1.555). Mean hemoglobin level during treatment was 10.72g/dL. Mean reduction in hemoglobin levels was 2.07g/dL. The reduction in hemoglobin levels and the duration of therapy were correlated (p-value <0.05). The severity of anemia was related to age of the patients (p-value <0.05) but not with gender and RBC morphology. Conclusion: Ribavirin induces anemia. The duration of ribavirin therapy and initial hemoglobin levels were related to the severity of anemia, significant enough to cause dose modification and subsequently suboptimal levels affecting efficacy. In return hemoglobin reduction, dose modification and age of the patient were also related.


Vacunas ◽  
2020 ◽  
Vol 21 (2) ◽  
pp. 95-104 ◽  
Author(s):  
Y.M. AlGoraini ◽  
N.N. AlDujayn ◽  
M.A. AlRasheed ◽  
Y.E. Bashawri ◽  
S.S. Alsubaie ◽  
...  

Author(s):  
Nandini Chatterjee ◽  
Supratick Chakraborty ◽  
Mainak Mukhopadhyay ◽  
Sinjon Ghosh ◽  
Bikramjit Barkandaj ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document